*Applications will be reviewed on a rolling-basis.
A postdoctoral fellowship opportunity is currently available in the Division of Molecular and Genetic Toxicology, National Center for Toxicological Research (NCTR) of the U.S. Food and Drug Administration (FDA) Jefferson Laboratories Campus located in Jefferson, Arkansas.
The majority of drugs administered during pregnancy lack appropriate information on embryo/fetal safety. To address this FDA regulatory need, the selected participant will use a model that combines human embryonic stem cells (hESCs) as an in vitro surrogate of the developing embryo with a placental barrier to evaluate the risks associated with placental drug transfer. Collaborative activities include: 1) differentiating hESCs into cardiomyocytes or neurons for use in evaluating risks associated with placental drug transfer, and measuring a panel of general toxicity and cardiac- and neuro- developmental toxicity endpoints; 2) following completion of toxicology studies, analyzing gene expression and epigenetic profiles as well as mutation induction in response to drug exposure and identify sensitive biomarkers of embryo-fetal toxicity. The participant will collaborate with FDA investigators at NCTR and with investigators in other FDA centers. During the project, the participant will be actively encouraged to present the research at internal and external meetings and publish the findings in peer-reviewed journals.
Anticipated Appointment Start Date: Spring 2021
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Jefferson, Arkansas, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.
FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:
- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow’s obligation to protect and not to further disclose or use non-public information.
The qualified candidate should have received a doctoral degree in one of the relevant fields, or be currently pursuing the degree with completion by May 31, 2021. Degree must have been received within five years of the appointment start date.
- Thorough knowledge in the area of Toxicology, Cell biology or Molecular Biology, Physiology and Developmental Biology
- Previous experience with cell culture and molecular biology techniques
- Demonstrated written and oral communication skills